Discovery of new Hsp90-Cdc37 protein-protein interaction inhibitors: in silico screening and optimization of anticancer activity

The interaction between heat shock protein 90 (HSP90) and HSP90 co-chaperone cell-division cycle 37 (Cdc37) is crucial for the folding and maturation of several oncogenic proteins, particularly protein kinases. This makes the inhibition of this protein-protein interaction (PPI) an interesting target for developing new Anticancer compounds. However, due to the large interaction surface, developing PPI inhibitors is challenging. In this work, we describe the discovery of new Hsp90-Cdc37 PPI inhibitors using a ligand-based virtual screening approach. Initial hit compounds showed HSP90 binding, resulting in Anticancer activity in the MCF-7 breast Cancer cell line. To optimize their antiproliferative effect, 35 analogs were prepared. Binding affinity for HSP90 was determined for the most promising compounds, 8c (K _d = 70.8 μM) and 13g (K _d = 73.3 μM), both of which interfered with the binding of Cdc37 to HSP90. This resulted in Anticancer activity against Ewing sarcoma (SK-N-MC), breast Cancer (MCF-7), and leukemia (THP-1) cell lines in vitro. Furthermore, compounds 8c and 13g demonstrated the ability to induce Apoptosis in the Ewing sarcoma cell line and caused a decrease in the levels of several known HSP90 client proteins in MCF-7 cells, all without inducing the heat shock response.